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ABSTRACT 
Objectives 
The present study aims to: i) calculate the cardiovascular disease (CVD) risk profile of an 
Ecuadorian hypertensive elderly sample using four different models: (1) the 2003 Systematic 
Coronary Risk Evaluation (SCORE) risk model, (2) the 2008 Framingham Risk Score (FRS, 
both using lipids profile and body mass index - BMI), (3) the 2013 AHA/ACC Pooled Cohort 
Equations model, and (4) the 2015 SCORE for Older Population - O.P., and; ii) assess the 
relationship between several independent variables: (1) dependence; (2) abuse; (3) creatinine; 
(4) estimated glomerular filtration rate (eGFR); (5) glucose; (6) HOMA-IR index;  (7) 
albumin; (8) thyroid stimulating hormone (TSH); (9) high-sensitivity C-reactive protein 
(hsCRP); and (10) vitamin D (25OHD)  serum levels and predicted CVD risk in the elderly 
according to each of the four tested models. 
 
Methods 
This cross-sectional study analyzed the Ecuadorian National Dataset of Health, Welfare and 
Aging in the Elderly (SABE-ECU) conducted in 2009. From 5235 subjects belonged to the 
original database, a sample of 951 participants was selected after excluded missing values. 
We estimated the predicted 10-year risk of CVD based on the four model equations 
previously mentioned. In addition, logistic regression models were used to find odds ratios 
(OR) and corresponding 95% confidence intervals (CI) between proposed novel 
cardiovascular risk factors and predicted CVD risk.  
 
Results 
In 2009, one-third of the Ecuadorian hypertensive elderly population is allocated in the “high 
CVD risk” category according to the four equations used. In the adjusted logistic regression 
model, low eGFR (<60 ml/min, OR 0.23, [0.06-0.92]), low albumin serum level (<3.5 g/dl, 
OR 8.09, [1.63-40.04]), high HOMA-IR index (≥3.2, OR 2.01, [1.22-3.30]), and high hsCRP 
serum level (≥1.1 mg/L, OR 2.00, [1.12-3.58]) showed association with CVD risk when 
using FRS and SCORE O.P. models. 
 
Conclusion 
We found that low eGFR, high HOMA-IR index, low albumin and high hsCRP serum levels 
are independently and significantly associated with CVD risk in the study individuals. These 
laboratory variables could be included as predictor markers for CVD risk in future elder-
validated scores. More studies are needed to assess the complex interaction between aging, 
hypertension, nutritional status, insulin resistance, inflammation, and CVD risk in the aged 
population. 
 
Key words: coronary heart disease, cardiovascular risk, elderly, hypertension, kidney disease, 
nutritional status, insulin resistance, inflammation, predictive model, multinomial logistic 
regression. 
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INTRODUCTION 
Background  
Between 2015 and 2030, the number of older persons — those aged 60 years or over — in 
the world is projected to grow by 56 percent, from 901 million to more than 1.4 billion [1]. 
With this change in demographics, the risk of age-related, non-communicable diseases will 
increase. Given the presence of known risk factors, it is not surprising to find metabolic 
syndrome (MetS) [2] and coronary heart disease (CHD) [3] within this age group, conditions 
which increase the relative risk to develop cardiovascular disease (CVD), a disorder that 
accounts for 30% of deaths worldwide [4]. In order to predict the future development of 
CVD, several risk scores and equations have been established [5-16]. However, most of these 
models were developed in middle-aged populations. It is uncertain whether risk estimates 
based on these scores can be generalized to the elderly. Indeed, recent work from a number of 
studies has shown that these conventional models, validated in middle-aged populations, 
perform poorly in predicting cardiovascular risk in the elderly, tending to overestimate actual 
risk [17, 18].  
The absolute risk of vascular disease increases with advancing years, being age a 
massively recognized CVD risk factor [19]. However, the relative contribution of age and 
other conventional risk factors to overall CVD risk decreases in the elderly [20, 21]. 
Moreover, it has been proposed that traditional CVD risk factors in the old population show a 
phenomenon termed “reverse epidemiology” or “risk factor paradox”, according to which 
body mass index (BMI), serum cholesterol, and blood pressure (BP) are also found to relate 
to CVD outcomes in the geriatric population, but in an opposite direction [22]. This fact does 
alter the mathematical behavior and, consequently, the logarithmic coefficients used to 
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predict CVD risk in the elderly when incorporating these independent factors into 
multivariate risk prediction equations.  
A number of studies have attempted to validate existing models in older populations 
[23-26]. Overall, these have found the tool unsuitable for use in the majority of older adults, 
particularly those at lower risk. Therefore, there is a need to assess the relationship between 
non-classical clinical and laboratory parameters and CVD risk in the elderly population. At 
the moment, some of those “potential” CVD risk factors (already proposed to be related with 
CVD risk profile, but uncertainly explored in the elderly population yet), include: (1) 
dependence/frailty status [27]; (2) elder abuse [28]; (3) creatinine [29, 30]; (4) estimated 
glomerular filtration rate (eGFR) [31]; (5) glucose [32]; (6) HOMA-IR [33]; (7) albumin [34-
36]; (8) thyroid stimulating hormone (TSH) [37-39]; (9) high-sensitivity C-reactive protein 
(hsCRP) [40-42]; and (10) vitamin D (25OHD, 25-hydroxivitamin D) [43, 44]. In addition, it 
does not exist data about the risk of CVD among the elderly population of Ecuador. 
 
Objectives 
The present study aims to: i) calculate the CVD risk in an Ecuadorian elderly sample using 
four different models: (1) the 2003 Systematic Coronary Risk Evaluation (SCORE) European 
Project CVD risk model [8], (2) the 2008 Framingham CVD risk model (FRS) [13], (3) the 
2013 AHA/ACC Pooled Cohort Equations model [14], and (4) the 2015 SCORE for Older 
Persons - O.P. [26]; and ii) assess the relationship between several independent variables: (1) 
dependence/frailty status -for basic activities of daily living (BADL) determined by Katz 
scale [45], and for instrumental activities of daily living (IADL) determined by Lawton & 
Brody scale [46]; (2) elder abuse -either physical, psychological, neglect or exploitation, 
determined by Bass AAT- [47]; (3) creatinine; (4) estimated glomerular filtration rate 
(eGFR); (5) glucose; (6) HOMA-IR, (7) albumin; (8) thyroid stimulating hormone (TSH); (9) 
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high-sensitivity C-reactive protein (hsCRP); and (10) vitamin D and CVD risk in elderly 
hypertensive patients. 
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METHODOLOGY 
Setting 
The geographic setting of this study was the country of Ecuador, located in South America. 
In 2009, the Ecuadorian government conducted a national survey, entitled Encuesta sobre 
Salud, Bienestar y Envejecimiento (SABE-ECU – Survey of Health, Wellbeing and Aging), 
to investigate the health and well-being of elderly people, based on a representative sample 
(n= 5235) of persons aged from 60 years and over [48]. The modules included in the survey 
were demographic and household characteristics; self-reported health and chronic conditions; 
anthropometric measures; mobility status, abuse and cognitive states; use and access of health 
services; medication use; family and social support, and labor force and retirement. 
 
Study Design, Participants and Data Sources 
This cross-sectional study analyzed the national dataset of Health, Welfare and Aging in 
Ecuadorian elderly population conducted during 2009 [48]. Participants included in this study 
were man and women older than 60 years of age, living in urban and rural areas of the coast 
and highlands of Ecuador. The model under which the representative sample for the study 
was selected included a probabilistic and two-stage design, proportional to the size of the 
existing elderly Ecuadorian population according to the final data and mapping of the VI 
Census of Population and V Census of Housing, held in November 2001. Overall, 5235 
subjects belonged to the original database, but 4284 subjects were progressively excluded due 
to missing values (Figure #1).  
 
Testing Instruments 
This study applied two elder-validated scales to evaluate dependence status. The Katz Basic 
Activities of Daily Living Scale (BADL) consists of six items (bathing, dressing, toileting, 
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transferring, continence, and feeding), hierarchically ordered according to the sequence in 
which patients lose and regain independence to perform them [45]. The scale assigns each 
item one point if done independently by the subject or with little assistance, or zero points if 
required a great help to be done or directly not realized. According to the total score, patients 
are classified into seven groups, where A is the maximum independency and G at the 
maximum dependency. In the present study, a summary score of zero was considered to be 
independency, with any other value allocated as dependency.  
The Lawton Instrumental Activities of Daily Living Scale (IADL) is an appropriate 
instrument to assess independent living skills, measuring eight domains of functional status 
(using the telephone, shopping, preparing food, housekeeping, doing laundry, using 
transportation, handling medications, and handling finances) [46]. Women are scored on all 8 
areas of function; historically, for men, the areas of food preparation, housekeeping, 
laundering were excluded. However, current recommendations are to assess all domains for 
both genders [49]. In the present study, all individuals were scored according to their highest 
level of functioning in each category, with a summary score of 8 considered independency 
and any other value catalogued as dependency.  
In addition, an elder-validated questionnaire was used to assess physical-
psychological abuse, as well as neglect and exploitation. The Bass Actual Abuse Tool (AAT) 
provides a list of the major forms of abuse and violence, with a single check already 
indicating domestic maltreatment [47]. In the present study, the existence of one or more of 
the indicators from the AAT list was already considered elder abuse. 
Estimated glomerular filtration rate (eGFR) was calculated using the validated 
Modification of Diet in Renal Disease (MDRD) equation (see Appendix C) [59]. Insulin 
resistance was quantified applying the well-known Homeostatic Model Assessment (HOMA) 
index [92]. 
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Finally, four different equations to calculate CVD risk in the elderly were used: (1) 
the 2003 SCORE European Project CVD risk model [8], (2) the 2008 Framingham CVD risk 
score (FRS, with both sub-equations using the lipids profile or BMI) [13], (3) the 2013 
AHA/ACC Pooled Cohort Equations model [14], and (4) the 2015 SCORE for Older 
Population – O.P. model [26]. In general, these models are derived multivariable 
mathematical functions that assign weights to major CVD risk factors such as sex, age, race, 
blood pressure, total cholesterol, high-density lipoprotein cholesterol, smoking behavior, and 
diabetes status, to produce a probability estimate of developing CHD within a certain period 
(e.g., the next 10 years). However, many features differentiate each one of the equations. FRS 
was developed based on a population 30-74 years old [13], while SCORE model was applied 
for 19-80 years old patients [8]. The 2013 ACC/AHA model pooled several cohorts with 40-
79 years old subjects, and includes “race” as risk factor [14]. The “high risk” threshold for 
FRS and 2013 AHA/ACC models is 20% [14], whereas for SCORE model is only 5% [8]. 
Additionally, FRS model is only intended to predict CHD risk [13], whilst 2003 SCORE 
model prognosticates total-CVD risk (particularly fatal events occurrence probability) [8]. 
The 2015 SCORE for Older Persons – O.P. is an adaptation proposed by Cooney et al. 
intended to provide improved accuracy in total-CVD risk estimation than original SCORE in 
old patients [26]. The 2013 ACC/AHA model predicts atherosclerotic cardiovascular disease 
(ASCVD), defined as coronary death or nonfatal myocardial infarction, or fatal or nonfatal 
stroke [14].  
 
Variables and Statistical Analysis 
Descriptive statistics were used to characterize the demographic and CVD risk (low-moderate 
vs. high) data retrieved from the study participants. Continuous variables are described as 
mean ± standard deviation (SD), and categorical variables as counts and percentages. To 
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predict the 10-year risk of developing CVD in this elderly population we used the four model 
equations and regression coefficients as described in the Appendix A. Unless otherwise 
specified, we used a knowledge of prior studies and univariate screen (Chi Square test, 
independent sample t-test or Fisher’s exact test, as appropriate) approach at a level of p-value 
<0.05 to identify the potential independent variables to be included in the adjusted model. 
 Multinomial logistic regression was used to quantify the odds ratios (OR) and 
corresponding 95% confidence intervals (CI) between proposed independent variables and 
CVD risk according to each of the four used model equations. When necessary, laboratory 
continuous variables were transformed to categorical variables according to most widespread 
Merck Manual cut-offs [50]. Results with statistical significance were those with a p-value 
less than 0.05. The software used was SPSS 22.0 Software Statistics Platform.  
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RESULTS 
This cross-sectional study analyzed information from the SABE-ECU national dataset. All 
SABE-ECU participants aged 60 years and older without a history of self-reported CVD were 
studied. The final study population consisted of 951 subjects (Figure #1).   
 
Figure #1: Flowchart describing selection of subjects and final sample of the study. 
 
Universe: 5235 Ecuadorian elderly >60 years 
old without a history of self-reported CVD 
1512 excluded cases:  
lack of data concerning confirmed age 
105 excluded cases:  
lack of data concerning blood pressure, height and/or weight 
2053 excluded cases:  
lack of data concerning lab values 
614 excluded cases:  
lack of data concerning ethnicity, scholarship, and dependence/frailty status 
Final sample: 951 subjects 
598 females 
353 males 
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In the univariate analysis, we found differences between gender and place of residence, 
education level, dependence status (both for BADL and IADL), elder abuse, antihypertensive 
treatment, smoking status, prior diabetes mellitus diagnosis, creatinine, glucose, HOMA-IR, 
hsCRP, and vitamin D serum levels of the subjects (Table #1). The percentages of 
dependency according to Katz BADL scale and Lawton IADL scale found in the sample are 
considerable, with 313 (32.9%) being dependent for BADL and 372 (39.1%) being dependent 
for IADL.  
Moreover, the distribution of elder abuse in the study population was as follow: 90 
(9.5%) suffer physical abuse, 209 (22%) endure psychological abuse, 101 (10.6%) bear 
exploitation, and 78 (8.2%) withstand neglect by other, with a final prevalence of 277 
(29.1%) individuals suffering some form of abuse, exploitation and/or neglect. Finally, 
despite all the participants of the sample were previously diagnosed with hypertension, 391 
(41.8%) of the subjects did not receive appropriate antihypertensive therapy. 
Descriptive statistics regarding general CVD risk profile of the elderly Ecuadorian 
population according to all four tested CVD risk models can be found in Figure #2. Briefly, 
each one of the four tested CVD risk equations found different results. This phenomenon can 
be partially justified by the fact that, although all the four equations used have many variables 
in common, the outcome predicted by each one is slightly different (see Methodology, section 
Tested Instruments).  
Our results show that: (1) sixty nine percentage (when using FRS with lipids) and 
~76% (when using FRS with BMI) of the Ecuadorian elderly population is at high 10-year 
risk of developing coronary heart disease (CHD);  (2) 36.9% (when using SCORE) and 
58.8% (when using SCORE O.P.) of the population is at high total-CVD risk; and (3) 
according to AHA/ACC model, approximately 59.7% of the old adults in Ecuador is at high 
10-year risk of suffering atherosclerotic cardiovascular disease (ASCVD). 
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Each one of the selected independent variables, with respective odds ratios (OR) and 
confidence intervals of 95% (CI 95%) for both unadjusted and adjusted multinomial logistic 
regression models, are showed in Table #2. There are several interesting findings derived 
from this statistical analysis. First, there were many variables not usually related to CVD risk 
found in this model to be significant:  
(1) place of residency for AHA/ACC equation (rural as protective factor);  
(2) education level for FRS using lipids equation (High school or higher as protective 
factor);  
(3) Lawton scale for AHA/ACC and SCORE O.P. equations (dependent for IADV as risk 
factor);  
(4) Bass Scale for FRS using BMI equation (elder abuse as risk factor);  
(5) creatinine serum level for all four CVD risk equations (≥1.3 mg/dl as risk factor);  
(6) eGFR for FRS using BMI, SCORE, AHA/ACC, and SCORE O.P. equations (≥60 
ml/min as protective factor);  
(7) glucose serum level for FRS using lipids, using BMI and AHA/ACC equations (≥126 
mg/dl as risk factor);  
(8) albumin for FRS using BMI equation (<3.5 g/dl as risk factor);  
(9) HOMA-IR for FRS using lipids, SCORE, and SCORE O.P. equations (≥3.2 as risk 
factor); and  
(10) hsCRP for FRS using lipids equation (≥1.1 mg/dl as risk factor).  
Second, of all these variables found to be related to CVD risk through unadjusted 
analysis, only four of them showed statistical significance when examined with the 
multinomial logistic regression model adjusted for covariates:  
(1) eGFR for SCORE O.P. equation (≥60 ml/min as protective factor);  
(2) albumin for FRS using BMI equation (<3.5 g/dl as risk factor);  
18 
 
(3) HOMA-IR for FRS using lipids equation (≥3.2 as risk factor); and  
(4) hsCRP for Framingham using lipids equation (≥1.1 mg/dl as risk factor).  
Therefore, might be interesting to include each of these variables into its 
corresponding CVD risk equation, in order to predict an accurate CVD risk in elderly patients 
and perhaps a novel equation can be proposed incorporating these variables.  
Third, there were some variables not associated at all with CVD risk (not even in the 
multinomial logistic regression unadjusted model):  
(1) ethnicity, 
(2) living alone status, 
(3) Dependence status for BADV according to Katz scale, 
(4) TSH serum level, and 
(5) vitamin D serum level 
Interestingly, although 2013 AHA/ACC model uses “ethnicity” as a “breaking point” 
to classify subjects into Afro-American and non-Afro-American categories, when applied to 
our population, this equation did not correlate with significant p-values for this independent 
variable.
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Table #1. Baseline characteristics of the 
sample. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*p-value found using chi-square test. 
**p-value found using independent samples t-test 
***p-value found using Fischer’s exact test. 
α Dependence for basic activities of daily living (BADL) using 
Katz scale [42].  
β Dependence for instrumental activities of daily living (IADL) 
using Lawton scale [43]. 
γ Elder abuse using Bass Actual Abuse Tool (AAT) [44]. 
µ Estimated glomerular filtration rate (eGFR) calculated using 
MDRD formula [48].  
π Vitamin D measured in serum as 25-hydroxyvitamin D 
(25OHD).  
N/A p-value could not be calculated because all the cases were 
positive for only one possible option (everybody in the sample has 
been previously diagnosed with hypertension).
 
  
 
Variables 
Gender 
p-value Female 
(n=598) 
Male 
(n=353) 
Age (Mean ± SD), 
years 
71.22 ± 8.195 0.845** 
Age (categories) 
≤70 years old 322 (53.8%) 184 (52.1%) 
0.846* 71-80 years old 183 (30.6%) 110 (31.2%) 
> 80 years old 93 (15.6%) 59 (16.7%) 
Place of residence 
Urban 451 (75.4%) 227 (64.3%) 
<0.001* 
Rural 147 (24.6%) 126 (35.7%) 
Ethnicity 
Indigenous/Native 28 (4.7%) 26 (7.4%) 
0.304* 
Afro-American 18 (3.0%) 14 (4.0%) 
Mixed 414 (69.2%) 244 (69.1%) 
White 74 (12.4%) 39 (11%) 
Other 64 (10.7%) 30 (8.5%) 
Education level 
None/Primary 367 (81.4%) 250 (83.9%) 
0.01* Secondary/Technical 68 (15.1%) 27 (9.1%) 
College/Postgraduate 15 (3.3%) 21 (7.0%) 
Living alone/accompanied 
Alone 55 (9.2%) 32 (9.1%) 
0.946* 
Accompanied 543 (90.8%) 321 (90.9%) 
Dependence status for BADL (Katz) α 
0 (independence) 367 (61.4%) 271 (76.8%) 
<0.001* 
≥1 (dependence) 231 (38.6%) 82 (23.2%) 
Dependence status for IADL (Lawton) β 
8 (independence) 322 (53.8%) 257 (72.8%) 
<0.001* 
<8 (dependence) 276 (46.2%) 96 (27.2%) 
Elder abuse (AAT) γ 
Yes 191 (31.9%) 86 (24.4%) 
0.01* 
No 407 (68.1%) 267 (75.6%) 
Hypertension previously diagnosed 
Yes 598 (100%) 353 (100%) 
N/A 
No 0 (0%) 0 (0%) 
Antihypertensive treatment 
Yes 371 (62%) 189 (53.5%) 
0.01* 
No 227 (38%) 164 (46.5%) 
Smoking status 
Never 500 (83.6%) 97 (27.5%) 
<0.001* Former 85 (14.2%) 204 (57.8%) 
Current 12 (2%) 51 (14.4%) 
Diabetes mellitus previously diagnosed 
Yes 134 (22.4%) 55 (15.6%) 
0.01* 
No 464 (77.6%) 298 (84.4%) 
Creatinine (Mean ± 
SD), mg/dl 
0.8795 ± 0.4188 <0.001** 
Creatinine categories (mg/dl) 
≤1.3 581 (97.2%) 319 (90.4%) 
<0.001* 
>1.3 17 (2.8%) 34 (9.6%) 
eGFR (ml/min/1.73m2)µ 
<15 4 (0.7%) 0 (0%) 
0.712*** 
15-29.9 7 (1.2%) 5 (1.4%) 
30-59.9 64 (10.7%) 40 (11.3%) 
60-89.9 293 (49%) 169 (47.9%) 
≥90 230 (38.5%) 139 (39.4%) 
Glucose (Mean ± 
SD), mg/dl 
113.77 ± 45.495 <0.001** 
Glucose categories (mg/dl) 
<126 481 (80.4%) 308 (87.3%) 
0.007* 
≥126 117 (19.6%) 45 (12.7%) 
HOMA-IR 
<3.2 318 (53.2%) 261 (73.9%) 
<0.001* 
≥3.2 280 (46.8%) 92 (26.1%) 
Albumin (g/dl) 
<3.5 (low) 8 (1.3%) 10 (2.8%) 
0.102* 
≥3.5 (normal) 590 (98.7%) 343 (97.2%) 
TSH mIU/L 
<5 (low-normal) 382 (63.9%) 206 (58.4%) 
0.09* 
≥5 (high) 216 (36.1%) 147 (41.6%) 
hsCRP (Mean ± 
SD), mg/L 
5.52 ± 9.67 0.942** 
hsCRP categories (mg/L) 
<1.1 (normal) 108 (18.1%) 97 (27.5%) 
0.001* 
≥1.1 (high) 490 (81.9%) 256 (72.5%) 
Vitamin D (Mean ± 
SD), ng/ml 
26.246 ± 10.65 <0.001** 
Vitamin D categories (ng/ml)π 
<15 (low) 63 (10.5%) 15 (4.2%) 
0.001* 
≥15 (normal) 535 (89.5%) 338 (95.8%) 
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Figure #2. Comparison of cardiovascular risk categories among the 2003 SCORE model, the 2008 Framingham Risk Score (FRS) using 
lipids and BMI equations, the 2013 AHA/ACC model, and the 2015 SCORE O.P. model.* 
 
 
 
 
*The y-axis reflect percentage of individuals. To compute both SCORE and SCORE O.P. European Project CVD risk models, Ecuador was assumed to be a “high CVD risk European land”, and that schema was used 
in the equation codification for SPSS (see Appendix A). The cut-off point between low, moderate and high CVD risk was determined, respectively, to be <10%, 10-20%, >20% for FRS and 2013 AHA/ACC models; and 
<1%, 1-5%, >5% for SCORE model; and <5%, 5-10%, >10% for SCORE O.P. model, agreeing with the references [7, 12, 13, 49]. 
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Table #2. Odds Ratios between significant independent variables and the general CVD risk according to each of the four tested 
equations.* 
 
Tested Equationβ 
10-year Framingham CVD risk 
model (using lipids profile) 
10-year Framingham CVD risk model 
(using BMI) 
SCORE European Project CVD risk 
modelα 
2013 AHA/ACC ASCVD risk Pooled 
Cohort Equations model 
SCORE O.P. 
Variables 
Unadjusted OR 
(95% CI) 
Adjusted OR 
(95% CI) 
Unadjusted OR 
(95% CI) 
Adjusted OR 
(95% CI) 
Unadjusted OR 
(95% CI) 
Adjusted OR 
(95% CI) 
Unadjusted OR 
(95% CI) 
Adjusted OR 
(95% CI) 
Unadjusted OR 
(95% CI) 
Adjusted OR 
(95% CI) 
Place of residency  
(rural/urban) 
0.75 
(0.56-1.01) 
1.11 
(0.63-1.93) 
0.79 
(0.58-1.1) 
0.78 
(0.42-1.46) 
0.81 
(0.59-1.08) 
0.65 
(0.38-1.11) 
0.74 
(0.56-0.99) 
0.65 
(0.34-1.24) 
0.93 
(0.7-1.24) 
0.72 
(0.29-1.79) 
Ethnicity (Afro-
American/Non-Afro-
American) 
1.13 
(0.52-2.49) 
0.87 
(0.28-2.77) 
1.39 
(0.56-3.42) 
0.87 
(0.25-3.09) 
1.36 
(0.67-2.77) 
0.86 
(0.29-2.58) 
1.13 
(0.55-2.35) 
2.44 
(0.52-11.31) 
1.18 
(0.57-2.43) 
0.93 
(0.10-8.64) 
Education level (High-
school or 
higher/Primary or less) 
0.73 
(0.55-0.97) 
0.69 
(0.47-1.02) 
0.83 
(0.61-1.13) 
0.81 
(0.52-1.26) 
0.94 
(0.71-1.24) 
0.92 
(0.62-1.36) 
0.89 
(0.68-1.16) 
0.82 
(0.51-1.31) 
0.98 
(0.74-1.28) 
0.87 
(0.45-1.67) 
Living alone status  
(yes/no) 
0.90 
(0.55-1.47) 
0.71 
(0.34-1.49) 
0.81 
(0.47-1.39) 
0.69 
(0.29-1.59) 
0.76 
(0.49-1.19) 
0.83 
(0.39-1.74) 
0.81 
(0.51-1.27) 
0.68 
(0.29-1.57) 
0.86 
(0.55-1.35) 
0.83 
(0.24-2.88) 
Katz scale 
(dependent/non-
dependent) 
0.96 
(0.72-1.28) 
1.10 
(0.69-1.75) 
0.98 
(0.72-1.35) 
1.14 
(0.68-1.93) 
1.01 
(0.76-1.34) 
1.29 
(0.81-2.08) 
1.09 
(0.83-1.44) 
0.81 
(0.47-1.41) 
1.15 
(0.87-1.51) 
0.66 
(0.31-1.44) 
Lawton scale 
(dependent/non-
dependent) 
0.98 
(0.74-1.31) 
0.92 
(0.57-1.47) 
1.06 
(0.78-1.45) 
0.84 
(0.49-1.43) 
1.21 
(0.92-1.58) 
0.77 
(0.47-1.29) 
1.6 
(1.22-2.09) 
0.81 
(0.46-1.44) 
1.97 
(1.50-2.59) 
0.52 
(0.22-1.22) 
Elder abuse  
(non-abused/ abused) 
0.75 
(0.56-1.02) 
0.94 
(0.58-1.51) 
0.66 
(0.48-0.91) 
0.65 
(0.38-1.12) 
1.11 
(0.83-1.48) 
1.22 
(0.76-1.95) 
0.83 
(0.62-1.09) 
1.08 
(0.6-1.94) 
0.92 
(0.69-1.23) 
0.77 
(0.34-1.76) 
Creatinine (mg/dl) 
(≥1.3/<1.3)  
4.31,  
(1.69-10.96) 
0.99 
(0.28-3.44) 
5.37 
(1.66-17.39) 
0.68 
(0.15-3.09) 
2.21 
(1.25-3.9) 
1.24 
(0.54-2.83) 
3.86 
(1.79-8.3) 
1.79 
(0.51-6.35) 
3.02  
(1.5-6.11) 
1.44 
(0.32-6.59) 
eGFR (ml/min/1.73m2) 
(≥60/<60) 
0.65 
(0.42-1.02) 
0.84 
(0.38-1.84) 
0.52 
(0.31-0.88) 
0.83 
(0.32-2.14) 
0.57 
(0.39-0.84) 
1.22 
(0.57-2.62) 
0.41 
(0.26-0.63) 
0.49 
(0.18-1.31) 
0.32 
(0.19-0.50) 
0.23 
(0.06-0.92) 
Glucose (mg/dl) 
(≥126/<126) 
2.96 
(1.87-4.68) 
1.62 
(0.76-3.45) 
1.91 
(1.21-3.01) 
0.81 
(0.34-1.91) 
0.76 
(0.53-1.09) 
1.51 
(0.71-3.22) 
1.59 
(1.11-2.28) 
1.98 
(0.78-5.02) 
1.16 
(0.82-1.64) 
1.84 
(0.52-6.47) 
Albumin (g/dl) 
(<3.5/≥3.5) 
0.87 
(0.31-2.45) 
2.16 
(0.49-9.56) 
1.22 
(0.43-3.45) 
8.09 
(1.63-40.04) 
1.51 
(0.53-4.28) 
2.24 
(0.24-21.43) 
1.19 
(0.46-3.03) 
0.81 
(0.15-4.31) 
1.42 
(0.57-3.65) 
0.82 
(0.03-20.41) 
TSH (mIU/L) 
(<5/≥5) 
1.05 
(0.79-1.4) 
1.34 
(0.85-2.09) 
0.94 
(0.69-1.27) 
1.18 
(0.71-1.96) 
1.26 
(0.96-1.65) 
1.29 
(0.84-1.99) 
1.07 
(0.82-1.39) 
1.28 
(0.75-2.18) 
1.01 
(0.78-1.32) 
0.76 
(0.35-1.64) 
HOMA-IR 
(≥3.2/<3.2) 
1.14 
(0.86-1.51) 
2.01 
(1.22-3.30) 
0.84 
(0.62-1.13) 
1.61 
(0.92-2.80) 
0.59 
(0.45-0.78) 
0.99 
(0.61-1.64) 
0.84 
(0.64-1.09) 
1.50 
(0.83-2.71) 
0.73 
(0.56-0.94) 
0.93 
(0.41-2.12) 
hsCRP (mg/L) 
(≥1.1/<1.1) 
1.19 
(0.86-1.65) 
2.00 
(1.12-3.58) 
0.86 
(0.59-1.24) 
1.06 
(0.55-2.06) 
1.28 
(0.92-1.78) 
1.61 
(0.96-2.70) 
0.98 
(0.72-1.34) 
1.24 
(0.67-2.33) 
0.96 
(0.70-1.32) 
1.26 
(0.49-3.21) 
Vitamin D (ng/ml) 
(<15/≥15) 
1.07 
(0.65-1.76) 
0.62 
(0.30-1.28) 
1.09 
(0.64-1.86) 
0.99 
(0.43-2.31) 
0.82 
(0.51-1.31) 
0.58 
(0.28-1.23) 
0.77 
(0.47-1.24) 
0.74 
(0.29-1.89) 
0.74 
(0.45-1.19) 
1.35 
(0.34-5.41) 
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*p-value, OR and IC 95% were found using several multinomial logistic regressions for each variable and adjusted or unadjusted for sex and the remaining significant variables (see Methodology). Significant p-values are depicted in bold, those of 
interest for the lector in red (found to be significant in the adjusted model). The reference category for the dependent variable is always high CVD risk/low-moderate CVD risk. 
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DISCUSSION 
General CVD risk profile of the Elderly Ecuadorian Population 
The predicted CVD risk profile of the elderly Ecuadorian population varies widely depending 
on the equation model used. As mentioned before, this phenomenon can be partially justified 
by the fact that, although all the four equations used have many variables in common, the 
outcome predicted by each one is slightly different (see Methodology, section Tested 
Instruments). However, one-third of this population is allocated in the “high CVD risk” 
category. A similar proportion of elders endures some form of dependence/frailty (either for 
BADL or IADL) and suffers abuse, exploitation and/or neglect.  
 
Demographics, Dependence Status, Elder Abuse and CVD risk 
In relation with our results, place of residency (urban/rural) and education level (primary or 
less/high-school or higher) were the only demographic variables found to be significantly 
related to CVD risk. Living in urban areas was found to be a CVD risk factor. This 
relationship could be explained by the fact that there are significant differences for 
anthropometric, metabolic, and blood pressure variables between rural and urban areas [51-
53]. As proposed by Das et al. (2008), living in urban/rural areas has a significant impact on 
central adiposity, lipid serum profile, lipoproteins, and blood pressure measures even after 
adjusted for age and sex [51]. In terms of education level, elderly who have completed only 
primary education or less were found to be statistically at higher 10-year CVD risk when 
compared with those with higher schooling. This finding could be attributed to the fact that 
people with higher education have a better capacity to understand their comorbidities, as well 
as the seriousness of their health-disease condition, being more empowered of their situation 
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and more capable of taking preventive measures to lower their CVD risk. So far, this is the 
first study to describe that association. 
Dependence status only for IADL (not for BADL) predicted by Lawton & Brody 
scale did correlate well with ASCVD risk when applying 2013 AHA/ACC model. Being 
dependent was found to be a significant CVD risk factor. In fact, this is the first study trying 
to correlate dependence status measured by Katz and Lawton scales with CVD risk, since 
most existing studies evaluate frailty and pre-frailty using Fried phenotype instead of Katz 
and Lawton ADL scales [27, 54-56].  
In the context of elder abuse, the International Network for the Prevention of Elder 
Abuse (INPEA) 2008 report of Elder Abuse in the Family in Spain, [57] found a prevalence 
of 10.5% for CVD in abuse victims, without testing the existence of a statistically significant 
relationship between both factors. A previous study found that elder abuse is associated with 
increased risk for metabolic syndromes, especially for those subjects who were younger 
elders, female, and had higher BMI [58]. To the present, our study is the first aimed to seek 
for a relationship between elder abuse (assessed by Bass AAT) and CVD risk, and found a 
predictable association when applying FRS using BMI equation. However, the potential 
causal mechanisms and temporal relations between specific subtypes of elder abuse and CVD 
risk are still not clearly understood, and require exhaustive cohort investigation. 
 
Low eGFR and CVD risk 
Four laboratory clinical measures were found to be significantly linked with CVD risk in 
multinomial logistic regression adjusted model. High eGFR (≥60 ml/min, measured with 
MDMR equation [59]) was found to be a protective factor for CVD risk predicted by SCORE 
O.P. equation, suggesting its potential usefulness to be included in elderly-modified versions 
of original SCORE model. Many plausible studies and pathophysiologic mechanism have 
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tried to sustain the relationship between low eGFR and CVD risk. According to Ghonemy et 
al. (2016), the increased inflammation and oxidative stress, which have an important role in 
the pathophysiology of coronary artery disease progression, could be associated with poorer 
renal function [60]. In addition, renal dysfunction may be associated with multiple other 
physiological changes, including high levels of hypercalcemia, hyperuricemia, homocysteine, 
anemia, and uremia, all of which have detrimental cardiovascular effects [60, 61]. Elevated 
asymmetric dimethyl arginine, reduced nitric oxide bioavailability, and endothelial 
dysfunction in kidney disease, which are associated with atherosclerosis, are also defined as 
factors linking impaired kidney function and CVD risk [61]. Additionally, in patients with 
chronic kidney disease (CKD), the renin-angiotensin and the sympathetic nervous systems 
are over stimulated and result in the increased production of superoxide, interleukin 6, and 
other pro-inflammatory cytokines. In addition, the activity of renalase, an enzyme produced 
by the kidneys that inactivates catecholamines, is decreased in patients with CKD [62].  
Certainly, patients with end-stage renal failure have greatly accelerated vascular 
disease and a high cardiac risk [60-63]. Consistently with results derived from this study, it 
has been already suggested that, given the effects of vascular disease on kidney function, it 
may serve as an essential indicator of vascular health [63]. 
 
Low albumin serum level and CVD risk 
Although the relationship between low albumin levels and CVD risk is not completely 
understood, several mechanism have been proposed. Hypoalbuminemia has been attributed to 
a variety of factors, including exogenous albumin loss, albumin distribution, catabolism rate 
of proteins, and the presence of inflammatory cytokines. Serum albumin concentrations are 
associated with increased inflammatory burden in the body. Inflammation has been 
associated with decreasing albumin synthesis rate and increasing catabolism [64]. 
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Experimental studies have suggested that high IL-6 and TNF-α levels, usually found in 
patients with low albumin levels, are associated with left ventricular remodeling, fetal gene 
expression, myocyte hypertrophy, and myocyte apoptosis [65].  
Another alternative explanation for albumin and CVD risk correlation is that 
comorbidities associated with development of CVD are also associated with worsening serum 
albumin profile (such as, for example, kidney disease). However, the multinomial logistic 
regression models proposed in this study have carefully assessed many possible confounding 
variables, which could potentially influence the association. In fact, controlling for all such 
predictors through an adjusted analysis did not change the association. These observations 
suggest an interesting role for serum albumin as a strong surrogate marker for CVD risk in 
the elderly, a marker that possibly integrates both known and unexplored pathways. Further 
insights are needed into anti-thrombotic, and anti-oxidant - oxidative stress mechanisms (due 
to the nitric oxide reservoir capabilities of albumin) [66], in order to fully characterize this 
association. 
 
High HOMA index, Insulin Resistance, Metabolic Syndrome and CVD risk 
The present study also found a statistically significant relationship between high HOMA-IR 
index (indicating insulin resistance) and CVD risk. Although establishing the 
pathophysiologic pathways linking insulin resistance to CVD is beyond the scope of the 
present study, it seems not out of place to mention that a number of mechanisms were 
identiﬁed through which an impaired insulin sensitivity could result in atherosclerosis. These 
mechanisms include the anti-aggregating platelet effect of insulin [67], the effect of the 
hormone on nitric oxide release from the endothelium [68], the inhibition by insulin of 
migration of vascular smooth muscle cells [69], and the inhibitory effect of the hormone on 
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ﬁbrinogen synthesis [70]. These potentially anti-atherogenic properties of insulin seem to be 
impaired in insulin-resistant states, and this might contribute to explain our results. 
On the other hand, many studies demonstrated that hyperinsulinemia, which generally 
coexists with insulin resistance, might promote atherosclerosis and CVD risk, through a 
potentially pro-atherogenic effect. The hormone enhances LDL cholesterol susceptibility to 
oxidation [71], promotes plasminogen activator inhibitor 1 [72] and endothelin-1 [73] release 
by several cells, and stimulates connective matrix and cholesterol synthesis and LDL receptor 
expression in the arterial wall [74]. Therefore, it can be suggested that the increased CVD 
risk observed in insulin-resistant states could stem from the perverse combination of the 
deﬁciency of anti-atherogenic effects of insulin, on the one side, and the presence of pro-
atherogenic effects of hyperinsulinemia on the other side. This hypothesis defines insulin 
resistance as a “selective phenomenon” that differently impairs multiple endocrine pathways, 
which finally enhance CVD risk. Such observation could also explain the finding that 
HOMA-IR index, for some equations, showed OR in the protective range (when applying 
SCORE and SCORE O.P.), whereas for other models showed OR in the risk range (when 
applying FRS with lipids). 
 
High hsCRP serum level and CVD risk 
High hsCRP serum levels also demonstrated statistically significant relationship with CHD 
risk predicted by FRS using lipids equation, being another potential independent CVD risk 
factor to be incorporated in that model.  There are many large studies that have linked high 
hsCRP serum levels with CVD risk, including the Physicians Heart Study (PHS) [75], the 
Texas Coronary Atherosclerosis Prevention Study (CAPS) [76], the Women’s Health 
Initiative (WHI) [77],  the Women’s Health Study (WHS) [78], the Cardiovascular Health 
Study (CHS) [79], the Framingham Heart Study (FHS) [80], and the Prospective Study of 
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Pravastatin in the Elderly at Risk (PROSPER) [81]. On the other hand, various other trials 
failed to find those significant associations, including the Multiple Risk Factor Intervention 
Trial (MRFIT) [82], the Québec Cardiovascular Study [83], the Rotterdam Study [84], and 
the Nurses’ Health Study (NHS) [85].  Based on evidence that has accrued, hsCRP serum 
measurement has been integrated into the Reynolds risk score (RRS) [11, 12], which has not 
been validated in the elderly population yet, but could eventually constitute a reliable 
alternative for old patients [86].  
In the context of the elderly population, the findings are still controversial. Jalal et al 
(2012) demonstrated that high hsCRP levels provide prognostic CVD risk information in 
elderly patients with chronic kidney disease (CKD) [41].  In the PROSPER (Prospective 
Study of Pravastatin in the Elderly at Risk) analysis of 5,804 elderly individuals, hsCRP 
levels minimally enhanced risk prediction (3.64 mg/l in those who had a CV event vs. 3.01 
mg/l in those who remained event free) [81]. Halil et al (2008), in an extensive analysis 
aimed to investigate the link between CHD risk determined by FRS and serum levels of 
ferritin, CRP, homocysteine, creatinine, and uric acid, did not find any significance for CRP 
[87].  
There are many other immunological-mediated proposed mechanisms to justify CRP 
and CVD risk association [88]. Zwaka et al. (2001) concluded that foam cell formation in 
human atherogenesis might be caused in part by uptake of CRP-opsonized native LDL [89]. 
Calabro et al. (2005) demonstrated in-vitro production of CRP by adipocytes isolated from 
human adipose tissue in response to inflammatory cytokines (IL-1-beta, IL-6, and resistin), 
thereby suggesting a new link between obesity and vascular inflammation [90]. More 
recently, Devaraj et al. (2011) provided data that CRP, via nitric oxide deficiency, promotes 
endothelial dysfunction by inducing release of circulating endothelial cells and endothelial 
micro particles, which are biomarkers of endothelial dysfunction [91].  
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Strengths and Limitations 
This study has several strengths. We used a risk estimation model validated for older men 
and women (SCORE O.P). Hence, overestimation of CVD risk is less likely to have occurred 
compared to the other risk-assessment models used in the analysis. Our study used data from 
a national survey that is representative of the Ecuadorian elderly population, which 
maximizing its external validity.  
 On the other hand, this research was limited by its cross-sectional design, thus making 
impossible to propose a new mathematical model for predicting CVD risk in the elderly by 
monitoring occurrence of new CVD fatal and non-fatal cases over time. Also, all subjects 
included in the sample were previously diagnosed with hypertension, leaving concerns about 
the influence of proposed CVD risk factors in non-hypertensive elderly patients. 
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CONCLUSIONS 
In summary, one-third of the Ecuadorian elderly population is allocated in the “high CVD 
risk” category. Four laboratory measures (eGFR, HOMA-IR index, albumin, and hsCRP 
serum levels) were independently correlated with CVD risk in hypertensive elderly patients 
when using FRS and SCORE O.P. models. The inclusion of these laboratory tests as 
predictor variables to estimate future  CVD events might be useful.  
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APPENDIX A: SPSS STATISTICS INFORMATICS 
 
The following is a detailed description of the process used to estimate the CVD risk 
applying three different models: (1) the 2008 FRS model [12], (2) the 2003 SCORE model 
[7], and (3) the 2013 AHA/ACC Pooled Cohort Equations model [13]. The main objective of 
this section is to make easily reproducible to other researchers the informatics procedure 
behind this study.  All the models previously described use many logarithmical expressions 
that are multiplied by specific coefficients, according to the subject’s sex, race and treated-
untreated hypertension specific condition.  Here the lector will find the codes introduced in 
the SPSS 22.0 Statistical Analysis Software in order to calculate the CVD risk with each 
model. We strongly recommend referring to Appendix B to adequately interpret those codes. 
 
Equations used to calculate 10-year Framingham CVD risk in subjects according to 
D’Angostino et al. (2008) 
As proposed by D’Angostino et al. (2008), the Framingham Heart Study offered two different 
equations to estimate CVD risk, one based on the subject’s lipid profile and the other based 
on the subject’s BMI.  
Using Lipids: 
Step 1: Obtain the general ∑βx real subtotal, according to each case: 
o Male not receiving antihypertensive treatment: 
∑βx REAL = (LN_EDAD * 3.06117) + (LN_PA_SIST * 1.93303) + 
(LN_COLEST_TOTAL * 1.1237) + (LN_COLEST_HDL*(-0.93263)) + (FUMAR_RECOD 
* 0.65451) + (DIAB_DX_RECOD * 0.57367) 
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o Male receiving antihypertensive treatment: 
∑βx REAL = (LN_EDAD * 3.06117) + (LN_PA_SIST * 1.99881) + 
(LN_COLEST_TOTAL * 1.1237) + (LN_COLEST_HDL*(-0.93263)) + (FUMAR_RECOD 
* 0.65451) + (DIAB_DX_RECOD * 0.57367) 
o Female not receiving antihypertensive treatment: 
∑βx REAL = (LN_EDAD * 2.32888) + (LN_PA_SIST * 2.76157) + 
(LN_COLEST_TOTAL * 1.20904) + (LN_COLEST_HDL*(-0.70833)) + 
(FUMAR_RECOD * 0.52873) + (DIAB_DX_RECOD * 0.69154) 
o Female receiving antihypertensive treatment: 
∑βx REAL = (LN_EDAD * 2.32888) + (LN_PA_SIST * 2.82263) + 
(LN_COLEST_TOTAL * 1.20904) + (LN_COLEST_HDL*(-0.70833)) + 
(FUMAR_RECOD * 0.52873) + (DIAB_DX_RECOD * 0.69154) 
Step 2: Calculate the risk score, depending on the subject’s sex: 
o Male: 
Risk Score = 1 − 0.88936exp(∑ βx REAL−23.9802) 
FRAM_RS1 = 1-(0.88936 ** EXP(Bx_REAL1-23.9802)) 
o Female: 
Risk Score = 1 − 0.95012exp(∑ βx REAL−26.1931) 
FRAM_RS1 = 1-(0.95012 ** EXP(Bx_REAL1-26.1931)) 
Using BMI 
Step 1: Obtain the general ∑βx real subtotal, according to each case: 
o Male not receiving antihypertensive treatment: 
∑βx REAL = (LN_EDAD* 3.11296) + (LN_PA_SIST * 1.85508) + (LN_IMC * 0.79277) + 
(FUMAR_RECOD * 0.70953) + (DIAB_DX_RECOD * 0.5316) 
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o Male receiving antihypertensive treatment: 
∑βx REAL = (LN_EDAD* 3.11296) + (LN_PA_SIST * 1.92672) + (LN_IMC * 0.79277) + 
(FUMAR_RECOD * 0.70953) + (DIAB_DX_RECOD * 0.5316) 
o Female not receiving antihypertensive treatment: 
∑βx REAL = (LN_EDAD* 2.72107) + (LN_PA_SIST * 2.81291) + (LN_IMC * 0.51125) + 
(FUMAR_RECOD * 0.61868) + (DIAB_DX_RECOD * 0.77763) 
o Female receiving antihypertensive treatment: 
∑βx REAL = (LN_EDAD* 2.72107) + (LN_PA_SIST * 2.88267) + (LN_IMC * 0.51125) + 
(FUMAR_RECOD * 0.61868) + (DIAB_DX_RECOD * 0.77763) 
Step 2: Calculate the risk score, depending on the subject’s sex: 
o Male: 
Risk Score = 1 − 0.88431exp(∑ βx REAL−23.9388) 
FRAM_RS2 = 1-(0.88431 ** (EXP(Bx_REAL2-23.9388))) 
o Female: 
Risk Score = 1 − 0.94833exp(∑ βx REAL−26.0145) 
FRAM_RS2 = 1-(0.94833 ** (EXP(Bx_REAL2-26.0145))) 
 
Equations used to calculate 10-year SCORE European Project CVD risk in subjects 
according to Conroy et al. (2008) 
Step 1: Calculate the underlying risks for coronary heart disease and for non-coronary 
cardiovascular disease separately for the person's age now and for their age in ten years time. 
In this study, we assumed Ecuador to be equivalent to a “high CVD risk European land”. The 
underlying survival probability is calculated depending on each case: 
o Male coronary heart disease underlying risk 
S0AGE_HRC = EXP(-(EXP(-21))*(EDAD_VERIF-20) ** 4.62) 
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S0AGE10_HRC = EXP(-(EXP(-21))*(EDAD_VERIF-10) ** 4.62) 
o Male non-coronary heart disease underlying risk 
S0AGE_HRNC = EXP(-(EXP(-25.7))*(EDAD_VERIF-20) ** 5.47) 
S0AGE10_HRNC = EXP(-(EXP(-25.7))*(EDAD_VERIF-10) ** 5.47) 
o Female coronary heart disease underlying risk 
S0AGE_HRC = EXP(-(EXP(-28.7))*(EDAD_VERIF-20) ** 6.23) 
S0AGE10_HRC = EXP(-(EXP(-28.7))*(EDAD_VERIF-10) ** 6.23) 
o Female non-coronary heart disease underlying risk 
S0AGE_HRNC = EXP(-(EXP(-30))*(EDAD_VERIF-20) ** 6.42) 
S0AGE10_HRNC = EXP(-(EXP(-30))*(EDAD_VERIF-10) ** 6.42) 
 
Step 2: Calculate the weighted sum, w, of the risk factors cholesterol, smoking and systolic 
blood pressure. Two weighted sums will have to be calculated, one for coronary heart disease 
and one for non-coronary cardiovascular disease. Smoking is coded as 1 for current and 0 for 
non-smoker, so no value for smoking has to be entered if the person is a non-smoker. 
Cholesterol is measured in mmol/L and SBP is measured in mmHg. 
o Weighted sum for coronary heart disease underlying risk 
W_C = (0.24*(COLEST_TOTAL_MMOL-6)) + (0.018*(PA_SIST_PROM -120)) + 
(0.71*FUMAR_RECOD) 
o Weighted sum for non-coronary heart disease underlying risk 
W_NC = (0.02*(COLEST_TOTAL_MMOL-6)) + (0.022*(PA_SIST_PROM-120)) + 
(0.63*FUMAR_RECOD) 
 
Step 3: Combine the underlying risks for coronary heart disease and for non-coronary 
cardiovascular disease, at the person's age and at their age ten years from now (four 
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calculations) which were calculated in step 1 with the weighted sum of a person's risk factors 
from step 2 for the two end-points, coronary heart disease and non-coronary cardiovascular 
disease to get the probability of survival at each age for each cause. 
o Male/Female combined coronary heart disease underlying risk 
S0AGE_HRC2 = S0AGE_HRC ** W_C 
S0AGE10_HRC2 = S0AGE10_HRC ** W_C 
o Male/Female combined non-coronary heart disease underlying risk 
S0AGE_HRNC2 = S0AGE_HRNC** W_NC 
S0AGE10_HRNC2 = S0AGE10_HRNC** W_NC 
 
Step 4: For each cause, calculate the 10-year survival probability based on the survival 
probability for the person's current age and their age in 10 years time: 
o Male/Female 10-year survival probability for coronary heart disease  
S10_C = S0AGE10_HRC2/S0AGE_HRC2 
o Male/Female 10-year survival probability for coronary heart disease 
S10_NC = S0AGE10_HRNC2/S0AGE_HRNC2 
 
Step 5: Calculate the 10 year risk for each end-point as follows: 
o Male/Female 10-year risk for coronary heart disease  
RISK10_C = 1 - S10_C 
o Male/Female 10-year risk for coronary heart disease  
RISK10_NC = 1 - S10_NC 
 
Step 6: Combine the risks for coronary heart disease and non-coronary cardiovascular 
disease by adding them: 
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o Male/Female 10-year CVD risk 
SCORE_RISK = RISK10_C + RISK10_NC 
 
Equations used to calculate the 2013 AHA/ACC 10-year race- and sex-specific ASCVD 
risk (Pooled Cohort Equations) in subjects according to Goff et al. (2013) 
Step 1: Obtain the “individual sum value”, depending on the subject’s race and sex: 
o Non-black female not receiving antihypertensive treatment: 
NBF_INDIV_SUM = (LN_EDAD * (-29.799)) + ((LN_EDAD **2)*4.884) + 
(LN_COLEST_TOTAL * 13.540) + (LN_EDAD*LN_COLEST_TOTAL*(-3.114)) + 
(LN_COLEST_HDL*(-13.578)) + (LN_EDAD*LN_COLEST_HDL*3.149) + 
(LN_PA_SIST*1.957) + (FUMAR_RECOD * 7.574) + (LN_EDAD* FUMAR_RECOD*(-
1.665)) + (DIAB_DX_RECOD * 0.661) 
o Black female not receiving antihypertensive treatment: 
BF_INDIV_SUM = (LN_EDAD * 17.114) + (LN_COLEST_TOTAL * 0.940) + 
(LN_COLEST_HDL*(-18.920)) + (LN_EDAD*LN_COLEST_HDL*4.475) + 
(LN_PA_SIST*27.820) + (LN_EDAD* LN_PA_SIST*(-6.087)) + (FUMAR_RECOD * 
0.691) + (DIAB_DX_RECOD * 0.874) 
o Non-black female receiving antihypertensive treatment: 
NBF_INDIV_SUM = (LN_EDAD * (-29.799)) + ((LN_EDAD **2)*4.884) + 
(LN_COLEST_TOTAL * 13.540) + (LN_EDAD*LN_COLEST_TOTAL*(-3.114)) + 
(LN_COLEST_HDL*(-13.578)) + (LN_EDAD*LN_COLEST_HDL*3.149) + 
(LN_PA_SIST*2.019) + (FUMAR_RECOD * 7.574) + (LN_EDAD* FUMAR_RECOD*(-
1.665)) + (DIAB_DX_RECOD * 0.661) 
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o Black female receiving antihypertensive treatment: 
BF_INDIV_SUM = (LN_EDAD * 17.114) + (LN_COLEST_TOTAL * 0.940) + 
(LN_COLEST_HDL*(-18.920)) + (LN_EDAD*LN_COLEST_HDL*4.475) + 
(LN_PA_SIST*29.291) + (LN_EDAD* LN_PA_SIST*(-6.432)) + (FUMAR_RECOD * 
0.691) + (DIAB_DX_RECOD * 0.874) 
o Non-black male not receiving antihypertensive treatment: 
NBM_INDIV_SUM = (LN_EDAD * 12.344) + (LN_COLEST_TOTAL * 11.853) + 
(LN_EDAD*LN_COLEST_TOTAL*(-2.664)) + (LN_COLEST_HDL*(-7.990)) + 
(LN_EDAD*LN_COLEST_HDL*1.769) + (LN_PA_SIST*1.764) + (FUMAR_RECOD * 
7.837) + (LN_EDAD* FUMAR_RECOD*(-1.795)) + (DIAB_DX_RECOD * 0.658) 
o Black male not receiving antihypertensive treatment: 
BM_INDIV_SUM = (LN_EDAD * 2.469) + (LN_COLEST_TOTAL * 0.302) + 
(LN_COLEST_HDL*(-0.307)) + (LN_PA_SIST*1.809) + (FUMAR_RECOD * 0.549) + 
(DIAB_DX_RECOD * 0.645) 
o Non-black male receiving antihypertensive treatment: 
NBM_INDIV_SUM = (LN_EDAD * 12.344) + (LN_COLEST_TOTAL * 11.853) + 
(LN_EDAD*LN_COLEST_TOTAL*(-2.664)) + (LN_COLEST_HDL*(-7.990)) + 
(LN_EDAD*LN_COLEST_HDL*1.769) + (LN_PA_SIST*1.797) + (FUMAR_RECOD * 
7.837) + (LN_EDAD* FUMAR_RECOD*(-1.795)) + (DIAB_DX_RECOD * 0.658) 
o Black male receiving antihypertensive treatment: 
BM_INDIV_SUM = (LN_EDAD * 2.469) + (LN_COLEST_TOTAL * 0.302) + 
(LN_COLEST_HDL*(-0.307)) + (LN_PA_SIST*1.916) + (FUMAR_RECOD * 0.549) + 
(DIAB_DX_RECOD * 0.645) 
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Step 2: Calculate the final total ASCVD risk, according to the following equations: 
o Non-black female (either receiving antihypertensive treatment or not) 
NBF_ASCVD_RISK = 1-(0.9665 ** EXP(NBF_INDIV_SUM-(-29.18))) 
o Black female (either receiving antihypertensive treatment or not) 
BF_ASCVD_RISK = 1-(0.9533 ** EXP(BF_INDIV_SUM-86.61)) 
o Non-black male (either receiving antihypertensive treatment or not) 
NBM_ASCVD_RISK = 1-(0.9144 ** EXP(NBM_INDIV_SUM-61.18)) 
o Black male (either receiving antihypertensive treatment or not) 
BM_ASCVD_RISK = 1-(0.8954 ** EXP(BM_INDIV_SUM-19.54)) 
 
NOTE: SCORE O.P. CVD risk was calculated based on the same variables used for SCORE 
CVD risk estimation, only doing appropriate arrangements in the coefficients used according 
to Cooney et al. (2015) [26]. 
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APPENDIX B: IMPORTANT SPSS CODE’S 
GLOSSARY 
The following is the list of the most important variables necessary to adequately comprehend 
the informatics process explicated in Appendix A. Many codes depicted before have not been 
included in this chart, since their interpretation can be easily understood from the explanation 
paragraphs. 
SPSS Code 
Type of 
variable 
Label 
COLEST_TOTAL_MMOL Scale Total serum cholesterol (in mmol/L) 
CREA Scale Serum creatinine (in mg/dl) 
DIAB_DX_RECOD Nominal Diabetes mellitus previously diagnosed (yes/no) 
EDAD_VERIF Scale 
Verified age of the subject (using personal ID birth 
date) 
FUMAR_RECOD Nominal Smoking status of each subject (yes/no) 
LN_IMC Scale Ln of BMI of each subject (in kg/m
2
) 
LN_COLEST_HDL Scale Ln of serum HDL cholesterol (in mg/dL) 
LN_COLEST_TOTAL Scale Ln of total serum cholesterol (in mg/dL) 
LN_EDAD Scale Ln of EDAD_VERIF 
LN_PA_SIST Scale Ln of PA_SIST_PROM 
PA_SIST_PROM Scale 
Mean systolic blood pressure (of two different 
measures) of the subject in mmHg 
PESO_PROM Scale 
Mean weight (of two different measures) of the 
subject in kg 
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APPENDIX C: GFR ESTIMATION EQUATIONS 
We used the 4-variable MDMR Equation to estimate the GFR of the sample, as follows [48]: 
 Non-black male 
NBM_GFR = 186 * (CREA ** -1.154) * (EDAD_VERIF ** -0.203) 
 Black male 
BM_GFR = 186 * (CREA ** -1.154) * (EDAD_VERIF ** -0.203) * 1.210 
 Non-black female 
NBF_GFR = 186 * (CREA ** -1.154) * (EDAD_VERIF ** -0.203) * 0.742 
 Black female 
BF_GFR = 186 * (CREA ** -1.154) * (EDAD_VERIF ** -0.203) * 0.742 * 1.210 
 
 
 
